Bris­tol My­ers un­corks pos­i­tive PhI­II read­out for sub­cu­ta­neous Op­di­vo

Bris­tol My­ers Squibb’s sub­cu­ta­neous for­mu­la­tion of its can­cer block­buster Op­di­vo proved non­in­fe­ri­or to in­tra­venous Op­di­vo in a Phase III tri­al, the com­pa­ny

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER